IP-6 + Myo-Inositol

IP-6/myo-inositol ↑ NK cytotoxicity (lysis/CD107a), chelates iron (LIP ↓), ↓ VEGF/angio (tube ↓), + PI3K/MAPK for prolif/apopt/met ↓. Small trials biomarker/chemo support in CRC/prostate/breast/lung; 500–2000 mg PO safe but thrombosis caution—monitor iron/GI.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Supported by preclinical studies and small human trials; larger RCTs ongoing.Inositol HexaphosphateIP6Phytic AcidMyo-Inositol

Forms: Oral capsules (supplement, 500–2000 mg IP-6 + 100–500 mg myo-inositol)

Educational only, not medical advice. OncoForge makes no claim that IP-6 + Myo-Inositol treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Plant-derived combo that modestly chelates iron, boosts NK-cell activity, and downshifts angiogenesis/proliferation signals; small human studies suggest biomarker benefits and chemo support, but large oncology RCTs are scarce.

Evidence at a glance

Tier 3 · early humanColorectalProstateBreastLung

Moderate clinical (small trials/biomarkers) + strong preclinical; larger oncology RCTs needed.

How it may work

IP-6 (inositol hexaphosphate) and myo-inositol chelate iron, depriving cancer cells of essential metals for growth, while enhancing natural killer (NK) cell activity and immune surveillance. They inhibit angiogenesis by downregulating VEGF and suppress tumor proliferation through cell cycle arrest and apoptosis induction. The combination modulates PI3K/Akt and MAPK pathways, reducing metastasis. Human and animal studies show enhanced chemotherapy efficacy and reduced side effects in various cancers.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

NK-Cell Activity↑Enhances cytotoxicity; IFN-γ/IL-12 ↑
Iron Chelation↑Deprives tumor cells of iron; LIP ↓
Angiogenesis↓VEGF ↓; tube formation inhibition
Apoptosis↑Cell cycle arrest; PI3K/Akt/MAPK modulation
Metastasis↓Reduces via MMP-2/9 ↓

NKChelatorAngio

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

5-FU / Chemotherapy: Anti-tumor/metastasis in CRC.
EGCG: Angiogenesis inhibition.

Overlapping mechanisms

NK ↑ / Chelation ↑ / Angio ↓: Avoid stacking with other NK/iron/angio agents; risk GI/iron depletion without proportional gain.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Gi Upset MildIron Deficiency RiskThrombosis RiskPregnancy Caution

Potential interactions

Iron supplements / MultivitaminsSeparateModerateTheoreticalChelation reduces iron absorption.
Chemotherapy (e.g., 5-FU)ConsiderBeneficialTheoreticalEnhances efficacy/metastasis ↓ in CRC.
EGCGConsiderBeneficialTheoreticalAngiogenesis co-inhibition.

Timing

With meals: Reduces GI upset; enhances tolerance.
Divided TID: Steady levels; e.g., 400 mg x3.

References

Research

No published studies for IP-6 + Myo-Inositol yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of IP-6 + Myo-Inositol depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 500–2000 mg (po) Typical: 500–1200 mg/day IP-6 + 200–500 mg myo-inositol divided. Trials: Up to 2000 mg/day IP-6 for 3–6 months. Preclinical HED from mouse (0.4–1.6% diet) ~400–1600 mg/kg (~28–112 g for 70 kg); human uses ~1–2% of that for safety., From rice bran/legume extracts or pure. Divided TID with meals. Monitor ferritin/iron; cycle if long-term. Not Rx; recent thrombosis caution in cancer..

Trials studying IP-6 + Myo-Inositol

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar